» Articles » PMID: 31456745

Novel Personalized Dietary Treatment for Autism Based on the Gut-Immune-Endocrine-Brain Axis

Overview
Specialty Endocrinology
Date 2019 Aug 29
PMID 31456745
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental condition manifesting with impaired social interaction and communication, and restricted and repetitive behaviors and interests. In this perspective article, a more comprehensive approach than the gut-brain axis, hereby termed the "gut-immune-endocrine-brain" axis, is taken, based on which a personalized treatment plan for ASD is presented. ASD has no known etiology or cure, making desperate parents willing to try any treatment that worked for an individual with ASD, without much regard for its effectiveness, safety or side effects. This has been the case for restrictive dietary interventions as gluten-free/casein-free and ketogenic diets and recently, probiotics have emerged as the new such fad. One of the concerns about these dietary and probiotic treatments is their non-specificity: they may not be effective for all individuals with ASD, not all probiotic strains may have the beneficial qualities advertised indiscriminately for probiotics, and strains conferring benefits in one condition may not be probiotic in another. Not all children with ASD show immune reactivity to dietary proteins in wheat and milk, and wheat and milk may not be the only dietary elements to which reactivity is exhibited, where dietary aquaporins that resemble human aquaporins may elicit antibody reactivity in genetically susceptible individuals, which may include individuals with ASD. These observations are utilized to formulate a three-step plan to create effective, targeted, personalized treatments with as few side effects as possible, enabled by a systems approach connecting the various findings for dietary, immune, and neuroautoimmune reactivity in individuals with ASD.

Citing Articles

Exploring the interaction between the gut microbiota and cyclic adenosine monophosphate-protein kinase A signaling pathway: a potential therapeutic approach for neurodegenerative diseases.

Deng F, Yang D, Qing L, Chen Y, Zou J, Jia M Neural Regen Res. 2024; 20(11):3095-3112.

PMID: 39589173 PMC: 11881707. DOI: 10.4103/NRR.NRR-D-24-00607.


Autism in Turkey: demographics, behavior problems, and accompanying medical conditions in a sample of Turkish youth with autism spectrum disorder.

Doenyas C, Ekici B, Unay O, Gonen I, Tatli B Int J Dev Disabil. 2023; 69(2):179-189.

PMID: 37025343 PMC: 10071939. DOI: 10.1080/20473869.2021.1937001.


Probiotic Ameliorating Effects of Altered GABA/Glutamate Signaling in a Rodent Model of Autism.

Bin-Khattaf R, Alonazi M, Al-Dbass A, Almnaizel A, Aloudah H, Soliman D Metabolites. 2022; 12(8).

PMID: 36005593 PMC: 9416367. DOI: 10.3390/metabo12080720.


Dietary Intake, Nutritional Status and Sensory Profile in Children with Autism Spectrum Disorder and Typical Development.

Mendive Dubourdieu P, Guerendiain M Nutrients. 2022; 14(10).

PMID: 35631297 PMC: 9147144. DOI: 10.3390/nu14102155.


The Use of Probiotic Therapy in Metabolic and Neurological Diseases.

Lee S, Ahmad S, Lim Y, Zulkipli I Front Nutr. 2022; 9:887019.

PMID: 35592636 PMC: 9110960. DOI: 10.3389/fnut.2022.887019.


References
1.
Vojdani A, Campbell A, Anyanwu E, Kashanian A, Bock K, Vojdani E . Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol. 2002; 129(1-2):168-77. DOI: 10.1016/s0165-5728(02)00180-7. View

2.
Knivsberg A, Reichelt K, Hoien T, Nodland M . A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002; 5(4):251-61. DOI: 10.1080/10284150290028945. View

3.
Shattock P, Whiteley P . Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets. 2002; 6(2):175-83. DOI: 10.1517/14728222.6.2.175. View

4.
Jyonouchi H, Sun S, Itokazu N . Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002; 46(2):76-84. DOI: 10.1159/000065416. View

5.
Reichelt K, Knivsberg A . Can the pathophysiology of autism be explained by the nature of the discovered urine peptides?. Nutr Neurosci. 2003; 6(1):19-28. DOI: 10.1080/1028415021000042839. View